pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ELTROMBOPAG OLAMINE
drug · small molecule
save

ELTROMBOPAG OLAMINE

Marketedupdated 3mo ago
by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval10 co-mentions · 5 sources
  • tagSmall Molecule4 co-mentions · 4 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 2 investigational indications.

targets

Thrombopoietin receptor

all catalysts(3)

approval · 3
Jan 14, 2026
approval
$AMRX17.90-1.16%
7mo ago
ELTROMBOPAG OLAMINE — FDA approval
ELTROMBOPAG OLAMINE
→
Jan 14, 2026
approval
7mo ago
ELTROMBOPAG OLAMINE — FDA approval
ELTROMBOPAG OLAMINE
→
Jan 14, 2026
approval
7mo ago
ELTROMBOPAG OLAMINE — FDA approval
ELTROMBOPAG OLAMINE
→

Trials studying ELTROMBOPAG OLAMINE

  • phase2Eltrombopag for Peripheral Blood Stem Cell Harvestrecruitingn=46

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 1, 2027
345 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (54)

  • Feb 1, 2028patentUS 8052993*PED1.4y
  • Feb 1, 2028patentUS 8052993*PED1.4y
  • Feb 1, 2028patentUS 8052993*PED1.4y
  • Feb 1, 2028patentUS 8052993*PED1.4y
  • Feb 1, 2028patentUS 8052994*PED1.4y
  • Feb 1, 2028patentUS 8052994*PED1.4y
  • Feb 1, 2028patentUS 8052994*PED1.4y
  • Feb 1, 2028patentUS 8052994*PED1.4y
  • Feb 1, 2028patentUS 8062665*PED1.4y
  • Feb 1, 2028patentUS 8062665*PED1.4y
  • Feb 1, 2028patentUS 8062665*PED1.4y
  • Feb 1, 2028patentUS 8062665*PED1.4y
  • Feb 1, 2028patentUS 8071129*PED1.4y
  • Feb 1, 2028patentUS 8071129*PED1.4y
  • Feb 1, 2028patentUS 8071129*PED1.4y
  • Feb 1, 2028patentUS 8071129*PED1.4y
  • Feb 1, 2028patentUS 8828430*PED1.4y
  • Feb 1, 2028patentUS 8828430*PED1.4y
  • Feb 1, 2028patentUS 8828430*PED1.4y
  • Feb 1, 2028patentUS 8828430*PED1.4y
  • Aug 1, 2027formulationUS 8052993345d
  • Aug 1, 2027formulationUS 8052993345d
  • Aug 1, 2027formulationUS 8052993345d
  • Aug 1, 2027formulationUS 8052993345d
  • Aug 1, 2027formulationUS 8052994345d
  • Aug 1, 2027formulationUS 8052994345d
  • Aug 1, 2027formulationUS 8052994345d
  • Aug 1, 2027formulationUS 8052994345d
  • Aug 1, 2027formulationUS 8062665345d
  • Aug 1, 2027formulationUS 8062665345d
  • Aug 1, 2027formulationUS 8062665345d
  • Aug 1, 2027formulationUS 8062665345d
  • Aug 1, 2027formulationUS 8071129345d
  • Aug 1, 2027formulationUS 8071129345d
  • Aug 1, 2027formulationUS 8071129345d
  • Aug 1, 2027formulationUS 8071129345d
  • Aug 1, 2027formulationUS 8828430345d
  • Aug 1, 2027formulationUS 8828430345d
  • Aug 1, 2027formulationUS 8828430345d
  • Aug 1, 2027formulationUS 8828430345d
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jan 13, 2026patentUS 7547719*PED
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719
  • Jul 13, 2025compositionUS 7547719

News(0)

no news has mentioned this drug yet

brand
ELTROMBOPAG OLAMINE
trade names
Promacta, Promacta kit, Revolade
generic
ELTROMBOPAG OLAMINE
MOA
12.1 Mechanism of Action Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?